Page 96 - TD-4-3

Tumor Discovery Sorafenib induces MVPs in NSCLC

in NSCLC. By combining sorafenib with imipramine, our Further disclosure
studies demonstrated successfully reduced MVP release
and enhanced sorafenib’s cytotoxic activity in NSCLC Part of the findings have been presented in the Ohio Valley
Chapter of the Society of Toxicology Annual Meeting, West
cells. These observations build on accumulating evidence Lafayette, Indiana, USA (2023); Annual Boonshoft School
that MVP-focused interventions can potentiate the efficacy of Medicine Research Symposium, Dayton, Ohio, USA
of conventional and targeted therapies. Going forward, (2023); and 16 Annual Meeting of the Korean Society of
th
additional in vivo validation and clinical exploration Medical Oncology, Seoul, Korea (2023).
are warranted to determine whether this dual-targeting
strategy can translate into improved outcomes for patients References
with NSCLC.
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics
Acknowledgments 2022: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
None. 2024;74(3):229-263.

Funding doi: 10.3322/caac.21834
2. Society AC. Lung Cancer; 2024. Available from: https://www.
The financial support from the BSOM Medical Student cancer.org/cancer/types/lung-cancer.html [Last accessed on
Research Grant (Y.G. and M.H. with A.T. and R.P.S. as 2024 Dec 18].
mentors) and the NIH R21 grant ES033806 (R.P.S.) are
greatly appreciated. 3. Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell
lung cancer. Nat Rev Dis Primers. 2024;10(1):71.
Conflict of interest doi: 10.1038/s41572-024-00551-9

Ravi P. Sahu is an Editorial Board Member of this journal, 4. Hendrixson M, Gladkiy Y, Thyagarajan A, Sahu RP. Efficacy
but was not in any way involved in the editorial and of sorafenib-based therapies for non-small cell lung cancer.
peer-review process conducted for this paper, directly or Med Sci (Basel). 2024;12(2):20.
indirectly. Separately, other authors declared that they doi: 10.3390/medsci12020020
have no known competing financial interests or personal 5. Lin W, Wang X, Diao M, et al. Promoting reactive oxygen
relationships that could have influenced the work reported species accumulation to overcome tyrosine kinase inhibitor
in this paper. resistance in cancer. Cancer Cell Int. 2024;24(1):239.

Author contributions doi: 10.1186/s12935-024-03418-x
6. Weng MS, Chang JH, Hung WY, Yang YC, Chien MH.
Conceptualization: Anita Thyagarajan, Ravi P. Sahu The interplay of reactive oxygen species and the epidermal
Data curation: Yevgeniy Gladkiy, Anita Thyagarajan growth factor receptor in tumor progression and drug
Formal analysis: Yevgeniy Gladkiy resistance. J Exp Clin Cancer Res. 2018;37(1):61.
Investigation: Yevgeniy Gladkiy, Anita Thyagarajan
Methodology: Yevgeniy Gladkiy, Anita Thyagarajan, Ravi P. doi: 10.1186/s13046-018-0728-0
Sahu 7. Tsoupras A, Adamantidi T, Finos MA, et al. Re-assessing
Supervision: Anita Thyagarajan, Ravi P. Sahu the role of platelet activating factor and its inflammatory
Writing – original draft: Yevgeniy Gladkiy signaling and inhibitors in cancer and anti-cancer strategies.
Writing – review & editing: All authors Front Biosci (Landmark Ed). 2024;29(10):345.
doi: 10.31083/j.fbl2910345
Ethics approval and consent to participate 8. Haak VM, Huang S, Panigrahy D. Debris-stimulated
Not applicable. tumor growth: A pandora’s box? Cancer Metastasis Rev.
2021;40(3):791-801.
Consent for publication doi: 10.1007/s10555-021-09998-8

Not applicable. 9. Hackler PC, Reuss S, Konger RL, Travers JB, Sahu RP.
Systemic platelet-activating factor receptor activation
Availability of data augments experimental lung tumor growth and metastasis.
All datasets generated for this study are available from the Cancer Growth Metastasis. 2014;7:27-32.
corresponding authors on reasonable request. doi: 10.4137/cgm.S14501

Volume 4 Issue 3 (2025) 88 doi: 10.36922/TD025110019